Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.
Michael Rosenzweig, MD
Advertisement
Articles by Michael Rosenzweig, MD
Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.
Advertisement
Latest Updated Articles
Dr. Rosenzweig Discusses Emerging Agents in AmyloidosisPublished: April 27th 2018 | Updated:
Dr. Rosenzweig Discusses the Standard of Care in AmyloidosisPublished: May 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
2
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
3
Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD
4
Enfortumab Vedotin Dose Reductions May Improve Tolerability Without Impeding OS in Advanced Urothelial Carcinoma
5